Core Insights - Itron, Inc. released its 2024 Corporate Sustainability Report, emphasizing its commitment to sustainability and the positive impact of its solutions on customers and communities [1][2][3] Sustainability Strategy - The company completed its first enterprise-wide double materiality assessment in 2024, aligning sustainability priorities with stakeholder expectations and regulatory requirements [2][4] - Itron's ESG strategy is integrated into its operations, with oversight from the board of directors [3] Environmental Impact - Itron's solutions helped customers avoid 7.5 million metric tons of greenhouse gas emissions in 2024, driven by improved operational efficiency and consumer engagement [4] - The company achieved 100% ISO 14001 certification across all manufacturing facilities and reduced Scope 1 and 2 emissions by over 50% since 2019 [4] Community and Employee Engagement - Itron was recognized as one of America's Greatest Workplaces, with nearly 95% of employees expressing intent to stay with the company [4] - The company invested over $1 million in corporate philanthropy, educational outreach, and volunteerism [4] Ethical Conduct and Governance - In 2024, 100% of employees completed the Code of Conduct training, and nearly 90% of the Board remained independent [4] - Itron received an "AA" MSCI rating and a "Low Risk" designation from Sustainalytics, reflecting its strong ESG profile and values-driven leadership [4]

Company Overview - Iovance Biotherapeutics, Inc. is focused on innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for cancer patients [2] - The company aims to be a global leader in TIL therapies, utilizing the human immune system to target diverse cancer cells [2] - Iovance's Amtagvi is the first FDA-approved T cell therapy for a solid tumor indication, showcasing the company's commitment to continuous innovation in cell therapy [2] Upcoming Events - Senior leadership of Iovance Biotherapeutics will present at the Goldman Sachs Global Healthcare Conference on June 11, 2025, at 1:20 p.m. ET [1] - The presentation will be available via live and archived webcasts on the company's investor relations website [1] Product Development - The Iovance TIL platform has shown promising clinical data across multiple solid tumors, indicating potential for future growth and development [2] - The company is also exploring gene-edited cell therapy as part of its innovation strategy [2]

Core Insights - NeuroStar, a Silver Sponsor at the 13th Annual Clinical TMS Society (CTMSS) Meeting, is committed to clinical innovation and excellence in mental health care [1][2] - The company will present two significant poster presentations based on the TrakStar data set, which is the largest real-world outcomes database in TMS [2][3] - NeuroStar aims to optimize TMS efficacy and expand its use into new populations and protocols, reinforcing its leadership in the psychiatric community [3] Company Updates - NeuroStar will present a retrospective analysis comparing clinical outcomes between its proprietary Figure-8 coil and Brainsway's H-coil in treating depression [2] - The company is evaluating personalized qEEG-informed protocols for TMS therapy, demonstrating operational feasibility with the NeuroStar TMS System [4] - NeuroStar has delivered over 7.4 million treatments and operates Greenbrook TMS centers across the U.S. for treating Major Depressive Disorder (MDD) and other mental health disorders [6] Event Participation - The CTMSS Meeting will take place from June 11-14 in San Diego, CA, where NeuroStar will also participate in the PULSES Course for TMS providers [2] - Presentations will include data on elderly adults (age 70 and older) with MDD treated with TMS, and a retrospective analysis from 200 Greenbrook centers [7]

RANCHO CUCAMONGA, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- iPower Inc. (Nasdaq: IPW) ("iPower" or the "Company"), a tech and data-driven eCommerce service provider and online retailer, today announced a strategic partnership with Borg Rise U.S., a dynamic and fast-growing player in digital content and social media commerce. This partnership marks a key milestone in iPower’s strategy to expand its omnichannel presence through influencer-driven and content-based sales models across platforms like TikTok, Ins ...

New System Features Include Extended Flight Time, Higher Payload Capacity, Enhanced Stability, Advanced Radar, and Improved Cleaning DurabilityFT. LAUDERDALE, FL, June 10, 2025 (GLOBE NEWSWIRE) -- Duke Robotics Corp. (OTCQB: DUKR) ("Duke Robotics" or the "Company"), a leader in advanced robotics technology and autonomous drone solutions, today announced the launch of its next-generation Insulator Cleaning Drone System (ICDS2), representing a significant technological advancement in the Company's innovative ...

New collaboration combines Comscore’s trusted inventory rankings with Adelaide’s attention metrics, enabling advertisers to drive higher engagement and maximize campaign impactRESTON, Va., June 10, 2025 (GLOBE NEWSWIRE) -- Comscore (NASDAQ: SCOR), a global leader in measuring and analyzing consumer behaviors, today announced the expansion of its Comscore-Certified Deal IDs to include Adelaide’s attention-based metric in PubMatic’s premium sell-side supply including many of the top CTV publishers. Adelaide i ...

ISELIN, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the Scottish Medicines Consortium (SMC) acceptance of LYTENAVA™ (bevacizumab gamma) for use within NHS Scotland for the treatment of wet age-related macular degeneration (wet AMD). LYTENAVA™ (bevacizumab gamma) is the first and only licensed ophthalmic formulation of bevacizumab f ...

Major commercial expansion of its U.S. strategy through logistics and distribution agreementNEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, sports and other products, today announced a major expansion of its U.S. commercial strategy through an exclusive logistics and distribution agreem ...

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 30, 2025 to its short form base shelf prospectus dated May 15, 2025. MIAMI, June 10, 2025 (GLOBE NEWSWIRE) -- Digi Power X Inc. (“Digi Power X” or the “Company”) (Nasdaq: DGXX / TSXV: DGX), an innovative energy infrastructure company that develops data centers, is pleased to announce the release of the following report to shareholders by Michel Amar, Chairman and Chief Executive Office ...

Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is August 4th, 2025 SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for its annual Cytokinetics Corporate Giving Program. The program provides charitable donations to eligible non-profit organizations in the United States to support equitable healthcare initiatives for cardiovascular disease, diversity i ...